IndustryCompany release

Profound Medical Q3 revenue rises 86% to $9.8M as Cook Medical joins TULSA-PRO distribution

🇺🇸 Profound Medical Corp. (PROF) · Thu 05 Nov 2026

The prostate ablation maker also named Richard Fabian as incoming CEO and guided to at least $25.0 million in full-year revenue.

Profound Medical reported third-quarter 2026 revenue of about $9.8 million on 5 November, an 86% increase according to the company's headline. It also reported a gross margin of 78% and a sharply lower operating cash burn. The company did not give a cash-burn figure in the material available to us.

For the full year, Profound guided to revenue of at least $25.0 million.

The company also signed a U.S. supply and distribution agreement with the iMRI Division of Cook Medical. Under the deal, the TULSA-PRO prostate ablation system will be sold through Cook's Copernicus program. The material available to us does not give the agreement's financial terms, duration or rollout timetable.

Separately, Profound named Richard Fabian as its incoming chief executive officer, effective 14 January 2027. No further detail on the leadership transition was available to us.

What it means for your team

  • Market-access teams tracking prostate ablation should note that TULSA-PRO will gain a second U.S. commercial channel through Cook's iMRI Division, alongside the company's own sales effort.
  • Quality and supply-chain teams at U.S. hospitals may want to clarify how supply, service and complaint handling will be split between Profound and Cook under the new arrangement. The agreement's terms have not been disclosed.
  • A CEO change effective 14 January 2027 is a point to watch for any shift in commercial or regulatory strategy, though none has been announced.

Company's press release (SEC filing): Profound Medical Corp. ↗

Article written by VigiEye from the official source (Profound Medical Corp.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →